Not two clinics. Two different things.
Ways2Well, the Houston wellness practice founded by Brigham Buhler in 2018, and Celva are not really selling the same thing. They just happen to share the words "stem cell therapy" in how they are marketed.
The reason isn't preference, branding, or cost. It's the U.S. FDA. A clinic operating commercially inside the United States is bound by FDA's framework for human cells, tissues, and cellular and tissue-based products: and that framework does not currently allow commercial sale of expanded, allogeneic, cord-derived MSCs outside of FDA-cleared clinical trials. That's the category we deliver. It is, by law, off the menu in Texas.
This page is short. The honest comparison is mostly about what each clinic is structurally permitted to give you, and from there, what fits your goal. If you want to skip to the deep references on cell biology and FDA classification, the link cluster at the bottom is the fastest path.
One country's regulator draws the line. The line is the product.
In plain English: U.S. FDA classifies human cells along a spectrum. Cells that are autologous, minimally manipulated, intended for homologous use, and used on the same day fall under Section 361 these can be administered as a routine clinical procedure. Cells that are allogeneic, expanded in culture, or used non-homologously are classified as biologic drugs under Section 351. and require a full FDA-approved BLA (or an active clinical trial under IND) before commercial use.
Ways2Well, as a U.S. wellness practice, operates entirely on the Section 361 side. Celva, operating in Mexico under COFEPRIS, delivers a cGMP-manufactured biologic that sits squarely on the Section 351 side. We're describing the same body of regulation; we're each on a different side of it because of where we operate.
Section 361 HCT/P. Section 351 biologic drug. Same FDA. Different rules.
Same-day, minimally processed care that uses your own cells, drawn and returned within the same visit. Read § 1.1. the FDA line, plainly →
Expanded, allogeneic, donor-derived, cultured under cGMP. To sell commercially in the U.S. requires an approved BLA. There is no allogeneic UC-MSC product with that approval today. Read § 3.6. why these cells aren't the same →
That's the structural reason a U.S. wellness practice and a Mexican hospital program don't sell substitutable products. Ways2Well doesn't have a "lower-tier version" of what we deliver. They have a different cell category, the one their regulator permits commercially.
If the cell biology is different, the comparison stops being a comparison.
The two products diverge on five biological and operational dimensions. None of these are marketing distinctions, they're separately measurable properties of the material being administered.
The two products, biologically.
The honest summary. The Ways2Well offering and the Celva offering aren't ranked along the same axis, they're on different axes entirely. A patient choosing between them isn't comparing two prices for the same thing. They're comparing two different therapeutic categories.
This is also why a U.S. wellness practice's "stem cell" marketing reads as identical to ours from across the parking lot. The English words are the same. The product behind them is not. The deeper articles in the section below walk through cell biology in detail, start with § 3.6: Why stem cells aren't the same and § 3.2: Allogeneic vs. autologous.
The vial, the chart, the documentation.
Forget marketing language for a minute. Ask each clinic: what physical material enters your bloodstream, and what paperwork describes it? The two answers diverge cleanly.
The vial, the chart, the receipt.
One of these documents is a chairside procedure note. The other is a drug-substance release record traveling with a specific vial number. They aren't comparable; they're products of different regulatory worlds.
The cell-quality story is most of the story.
This page is intentionally short. The detailed work: what these cells actually are, why expansion matters, what cGMP means, why an allogeneic donor isn't a downgrade, lives in Section 3. If you read only one of the references below, read the first.
Why these aren't the same cells.
The single page every comparison in this section depends on. Donor, source, expansion, paperwork, the four axes that distinguish products.
Whose cells. Why a healthy, screened donor isn't a downgrade, and what your own cells can and can't give you when you're sick.
Three sources, three potency profiles. Why Wharton's jelly is the youngest, most-potent MSC source widely studied.
What "cGMP-compliant" really means: the cleanroom class, the SOPs, the release panel, the audit trail. The paperwork is the medicine.
The specific spec: count per kg, viability floor, passage cap, identity panel. What's on the CoA you receive.
Section 361 vs. Section 351. the regulation that creates the categorical gap between any U.S. wellness practice and Celva.
Ways2Well isn’t a cheaper version of us. It’s a different thing entirely.
Same English words, different therapeutic category. Ways2Well operates inside U.S. FDA framework, which permits autologous, minimally-manipulated, same-day-procedure regenerative care: and explicitly does not permit commercial sale of expanded, allogeneic, cord-derived MSC drug substance. That's not their choice; it's the law where they operate.
Celva delivers the category their regulator forbids, because we operate where it isn't forbidden, and we hand you the per-vial Certificate of Analysis that proves what entered the IV. If you're shopping U.S. regenerative options, Ways2Well is a real answer. If you're shopping expanded allogeneic UC-MSC, the comparison isn't us vs. them, it's us, or a U.S. clinical trial.